Tandem Diabetes CareTNDM
Recorded

Tandem Diabetes Care 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration48 minParticipants18

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good day, and welcome to the Tandem Diabetes Care Third Quarter 2026 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question, you will need to press star 11 on your touchtone telephone. Please note, this call may be recorded. I would like to turn the call over to Susan Morrison, Executive Vice President and Chief Administrative Officer.

Susan MorrisonEVP and Chief Administrative Officer

Please go ahead. Hello, and welcome to Tandem's 2026 Third Quarter Earnings Call.

Susan MorrisonEVP and Chief Administrative Officer

Today's discussion will include forward-looking statements, including statements about our CEO transition and its timing, our leadership, strategy, product pipeline, development timelines, financial performance, including profitability, and operating plans, and speak only as of today's date. These statements reflect our current expectations about future events and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in our forward-looking statements, which are described in our press release issued earlier today and under the risk factors portion of our most recent annual report on Form 10-K and quarterly report on Form 10-Q, as well as the Form 8-K we issued today. Today's discussion will also include references to both GAAP and non-GAAP financial measures.

Susan MorrisonEVP and Chief Administrative Officer

Please refer to our earnings release issued today and available on the Investor Center portion of our website for a reconciliation of non-GAAP measures to their most directly comparable GAAP financial measure and other information regarding our use of non-GAAP financial measures. In addition, we also issued a press release this afternoon on the planned evolution of Tandem's CEO leadership. To speak to this announcement, the chair of Tandem's Board of Directors, Beckie Robertson, will join us in opening today's call. We will then move to our third quarter earning results and company update from John Sheridan, President and CEO, and Leigh Vosseller, Executive Vice President and Chief Financial Officer. After their prepared remarks, we will open the call for questions with John and Leigh. Thank you in advance for limiting yourself to one question before rejoining the queue. I will now turn the call over to Beckie.

Beckie RobertsonChair of the Board of Directors

Thanks, Susan, and good afternoon, everyone. Today's succession announcement marks an important milestone for Tandem Diabetes Care. As part of a planned leadership transition, we celebrate John Sheridan's accomplished tenure as he prepares to retire at the end of 2026, and we are thrilled to welcome Jeannette Bankes as Tandem's next President and CEO. On behalf of the board, I want to thank John for more than a decade of service to Tandem, including eight years as CEO. Under John's leadership, Tandem has grown into a global innovator in diabetes care. He launched Control-IQ, our first hybrid closed-loop technology, advanced our digital health strategy, and expanded our portfolio with the introduction of Mobi. In addition, he established the foundation for Tandem to operate at scale internationally and set in motion business model changes that broadened customer access.

Beckie RobertsonChair of the Board of Directors

Just as important, he cultivated a mission-driven culture that will continue to define this company. With this foundation in place, Jeannette is the right leader to guide Tandem through its next phase of growth. Jeannette stood out during the board succession planning and search process, bringing more than 30 years of global operating experience and an impressive record of translating strategy into consistent execution and growth. Her experience scaling medical technology businesses is well-suited for Tandem at this stage as we capitalize on a new business model and expand internationally. Jeannette's customer-centric approach, broad perspective, and commitment to innovation align closely with Tandem's culture, mission, and priorities as we advance our technology roadmap, expand customer access, and pursue sustainable growth and profitability. She is also well-positioned to shape Tandem's long-term strategy and strengthen our competitive position.

Beckie RobertsonChair of the Board of Directors

Throughout the transition, our leadership team remains focused on Tandem's strategic priorities, and the board is confident in the organization's ability to deliver. John, thank you again for your leadership and your commitment to Tandem. Jeannette, we are excited to welcome you to the company on November 16th. With that, I'll turn the call over to John.

John SheridanPresident and CEO

Thank you, Beckie, and welcome, everyone, to our call today. It's been an honor to work alongside such an incredible group of employees and the board since 2013, and to have the privilege of leading this company for the past eight years. Together, we furthered Tandem's mission to improve the lives of people with diabetes. I am proud of all that we've accomplished, especially that half a million people worldwide now benefit from Tandem's technology. Tandem's fundamentals are strong, and I am confident in its future under Jeannette's leadership. She brings the experience, perspective, and commitment needed to build upon our momentum, and I look forward to supporting her through a smooth transition. Our team remains focused on executing our strategy and delivering value for customers and shareholders. With that, let's review our earnings results and the progress we're making across the business.

John SheridanPresident and CEO

Looking back on the third quarter and our year-to-date performance, I am proud of what Tandem has accomplished in 2026. We're executing on our strategic priorities to expand access to Tandem's life-changing technology while strengthening our business model, advancing our pipeline, and driving efficiency in our operations. These efforts are delivering tangible results. We outperformed across the P&L with increased contribution from our U.S. pharmacy transition and international shift to direct operations. Q3 also marked a quarter of record sales and pump shipments, with both growing double digits worldwide. This was supported by enhanced pricing and a return to year-over-year growth in U.S. new pump starts, and strong early demand for Tandem Mobi in the 12 countries where it's now available internationally. Beyond top-line growth, we're delivering significant margin expansion. This reflects focused execution on our efficiency initiatives and a balance between cost discipline and investment in growth.

John SheridanPresident and CEO

These recent accomplishments provide a solid foundation that position Tandem for long-term success. Today, we will provide more color on these results and review progress against our strategic priorities. Starting with reshaping our business model, we are undergoing major shifts in our approach to the global markets. In the U.S., after just two full quarters under PayGo reimbursement model, pharmacy sales have reached 15% of U.S. sales. We have steadily expanded access across the year and already achieved the high end of our full-year target, with approximately 50% formulary coverage. Early results in pharmacy demonstrate that the model is positioning us to achieve our goals of reaching more people through simplified access with lower upfront costs while driving greater economic benefit for our business.

John SheridanPresident and CEO

Outside the United States, we launched direct commercial operations in the U.K., Switzerland, and Austria earlier in the year, and remain on track to do the same in France this week. As one of our larger European markets, France represents an important next step for our international strategy. With this addition, we will be serving more than 30% of our international installed base directly. We plan to continue expanding our direct operations across 2027, which expands our footprint to approximately half of our installed base by the end of next year. Our early experience with direct international operations in 2026 confirms the strategic benefits of this approach as we develop closer relationship with customers and healthcare providers while achieving greater economic value. Turning to our pipeline advancements, we believe Tandem Mobi Tubeless is in the late stages of FDA review.

John SheridanPresident and CEO

Mobi Tubeless is designed to be the world's first and only tubeless AID system, offering up to seven days of wear. This new infusion site option converts an existing Mobi pump into a tubeless system. Users can switch between tubed and tubeless wear with the same rechargeable pump just by changing their supplies. Combining Control-IQ's best-in-class A1C outcomes with tubeless wear positions Tandem to compete in the fastest-growing segment of the pump market, with more wear options than any other system. Following clearance, we plan to begin a scaled commercial launch, expanding manufacturing capacity and updating pharmacy contracts. We are also excited to introduce healthcare providers to Mobi Tubeless and, pending clearance, are preparing to begin limited customer use and then expand to full commercial availability in the first half of 2027.

John SheridanPresident and CEO

To speed time to market, our initial submission focused on abdominal wear, and we will be working with the FDA to add more wear locations and insulin types. We also continue to innovate across our portfolio. Infusion set technology remains a key focus as we seek to improve comfort, extend wear time, reduce occlusions, and simplify the user experience. In Q3, we initiated a global launch of AutoSoft Plus, a new infusion set from our third-party supplier that is designed to improve ease of use with reliable one-hand insertion. AutoSoft Plus is now available in select countries, and we plan to expand to additional geographies in early 2027, pending any in-country regulatory requirements. This timing is important as we continue to manage supplier shortages of other infusion sets. We saw improved supply availability in Q3, and although improving, some level of impact remain into early 2027.

John SheridanPresident and CEO

We also plan to launch SteadiSet following Mobi Tubeless, our proprietary technology that is FDA cleared for wear up to seven days, further expanding our customers' choice in infusion sets. We also took meaningful steps in Q3 to progress our automated insulin delivery efforts. The pursuit of an algorithm worthy of the term artificial pancreas has been foundational to our vision, and as we shared in the last call, Tandem is closer than ever to this achievement. Building on our longstanding research partnership with the University of Virginia, Tandem is developing UVA's next-generation AIDANET algorithm into a fully closed-loop system. The system is designed to help people with type 1 and type 2 diabetes reach clinical time in range targets without meal announcements or other inputs, while still allowing users to enter additional information for a more personalized experience.

John SheridanPresident and CEO

We continue to advance the work necessary to begin a pivotal study before the end of 2026 in support of an FDA submission. With that, I'll turn the call over to Leigh for more details on our third quarter financial performance.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day